Company Overview
Biomerica, Inc. operates as a biomedical technology company focused on the development, patenting, manufacturing, and marketing of diagnostic and therapeutic products designed for the detection and treatment of various medical conditions and diseases on a global scale. The company functions within the healthcare sector, specifically targeting the medical devices industry, which involves creating tools and technologies essential for patient diagnosis and clinical treatment procedures. Its operational scale is defined by a market capitalization of $6.07M and an annual revenue of $4.46M over the trailing twelve months, supported by a workforce of 53 employees. These financial figures indicate that Biomerica is a micro-cap entity with limited revenue generation relative to its valuation, suggesting a position in the market characterized by high risk and significant potential for volatility rather than established market dominance or large-scale production capabilities.
Financial Health
The company reported a revenue of $4.46M for the trailing twelve months, yet this generated a net income of $-4,025,000 and an EBITDA of $-5,179,000, revealing a substantial gap between top-line sales and bottom-line profitability that points to a highly aggressive or inefficient cost structure. This financial dynamic is further evidenced by a free cash flow of $-1,701,375, which indicates that the company is currently burning cash rather than generating liquidity, thereby limiting its immediate financial flexibility and reliance on external capital sources for operations. An analysis of the three primary margins shows a gross margin of 5.6%, an operating margin of -113.5%, and a profit margin of -90.3%, where the deeply negative operating and profit margins suggest that operating expenses are significantly exceeding the value of the products sold. Despite these losses, the balance sheet holds $2.54M in cash against $284,000 in debt, resulting in a debt-to-equity ratio of 6.40 which, while indicating leverage, is offset by a healthy current ratio of 3.25 that demonstrates strong short-term liquidity and the ability to meet obligations due within a year. Return on Equity stands at -84.3% and return on assets is -49.4%, metrics that reveal that management has not yet been effective in generating returns on the capital invested or the assets employed in the business.
Valuation Assessment
The valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to the lack of positive earnings, while the forward P/E is 5.15, implying that the market expects earnings to turn positive in the future to justify this low multiple. The price-to-book ratio is 1.34, indicating that the stock is trading at a slight premium over its book value despite the company's current unprofitable status. Alternative valuation measures such as a price-to-sales ratio of 1.36 and an EV/EBITDA of -0.74 suggest that investors are pricing the company based on revenue multiples rather than earnings power, often seen in early-stage biotech or medical device firms. Regarding price action, the 52-week high is $5.92 and the 52-week low is $1.87, meaning the current trading price sits below the recent peak and reflects the volatility typical of small-cap healthcare stocks. The stock exhibits a beta of 0.23, which means its price volatility is significantly lower than the broader market, potentially offering a defensive characteristic relative to large-cap equities, although this low beta does not guarantee stability given the negative earnings environment.
Growth & Income
The company experienced a revenue growth rate of -26.0% year-over-year, while the earnings growth rate is N/A due to the absence of positive earnings, indicating that the business is currently in a contraction phase rather than an expansion phase. As a non-dividend payer, Biomerica has a dividend yield of N/A and a payout ratio of 0.0%, which confirms that the company does not distribute income to shareholders and instead reinvests its limited resources back into research and development to attempt to restore profitability. The overall growth and income profile for Biomerica is characterized by declining revenue, negative cash generation, and a lack of dividend income, reflecting the challenges inherent in developing and marketing specialized medical diagnostic test kits used to analyze blood, urine, and other biological samples.